Si può desiderare di provare un trattamento naturale disfunzione erettile come un diverso per i problemi di costruzione. Al giorno d oggi ci sono diverse terapie sul mercato, ma un trattamento naturale disfunzione erettile è stato confermato qualche ora e ora di nuovo per dare risultati efficienti e permanenti. Cos è la disfunzione sessuale? L incapacità di sviluppare o sostenere una costruzione abbastanza lungo per fare l amore è chiamato disfunzione erettile, ED https://farmacia-senzaricetta.it/ o (maschio) problemi di erezione. Tutti gli uomini possono avere problemi di costruzione di volta in volta e gli scienziati considerano ED essere presenti se si verificano problemi di costruzione almeno il 25% del tempo. Alcuni fatti duri: ED Può essere dovuto a problemi emotivi. Stress, pressione, giltiness, depressione, bassa autostima e ansia prestazioni può essere la causa dei vostri problemi di costruzione. La ricerca ha confermato che il 90 per cento della disfunzione erettile è fisica in origine, non emotiva. L impotenza colpisce la maggior parte degli uomini durante la loro vita e può essere dovuto a troppo colesterolo, problemi cardiaci, diabete, ipertensione, fumo o alcol. Alcuni rimedi possono essere la ragione. Le questioni legate al movimento sono collegate. Se ti occupi dei tuoi problemi di movimento, hai piu possibilita di risolvere questo problema. Qui ci sono 5 consigli facili su come aumentare la circolazione: 1. Mangia i pasti giusti. Questo ti rendera il flusso sanguigno ovvio. Una grande parte di rimanere sani e anche mantenere il flusso sanguigno ovvio è legato al vostro piano di alimentazione quotidiana e quello che si mangia. Una buona cura per la disfunzione erettile è mangiare un piano a basso contenuto di grassi e grande alimentazione di fibre. Mangiare fibre tutti i giorni e questo viene scoperto in prodotti cerealicoli cereali integrali, frutta e verdura. Evitare il più possibile pasti pronti o pasti non sani. 2. Wonder herbal rimedi. Molti rimedi vegetali per ED eseguire bene come possono migliorare il movimento. Hanno molto meno reazioni avverse rispetto ai farmaci convenzionali e si svolgono in modo efficiente per migliorare hardons e la forza, troppo. Erbe naturali come Ginkgo Biloba sono utilizzati come una strategia per ED. Gli specialisti di erboristeria credono anche che le spezie o le erbe come noce moscata, portano al movimento intorno al corpo, tra cui il pene. 3. Vitamine naturali vitali. Gli scienziati sanitari hanno scoperto che una mancanza di supplemento è tipico tra gli uomini con ED in particolare vitamina A. Se si ha una mancanza del nutriente ossido di zinco, Questo è stato confermato per portare alla disfunzione erettile. Queste inadeguatezze derivano dal fatto che molti valori nutrizionali in quello che mangiamo piano non sono sufficienti. Aggiungere al vostro fabbisogno di nutrienti aumenterà la circolazione del sistema e migliorare questa condizione. Gli integratori alimentari sono completamente naturali, quindi non dovrete preoccuparvi dei rischi di reazioni avverse. Inoltre, queste vitamine naturali sono utili per il vostro benessere over-all. Oltre a questi vantaggi benessere, disfunzione erettile vitamine naturali e integratori costano molto meno di farmaci rimedi. 4. Esercitare. Fai una mossa e non un tablet vibrante. Camminare farà di più per migliorare e sostenere hardons di qualsiasi altra compressa chimica nel lungo periodo. Il fitness fisico manterrà bassi livelli di pressione e mantenere grandi stadi di movimento. Andando per un 20-30 minuti di movimento rapido ogni giorno, può affrontare questo problema e può sostenere la vostra libido senza l uso di qualsiasi farmaco. 5. Sottolineare. Questo è il peggior attaccante per problemi di erezione. Scopri diversi metodi per riposare. Alcuni metodi tipici per riposare includono la lettura di un libro, la meditazione, un bagno rilassante o allenamenti di respirazione. Sto solo imparando alcuni semplici allenamenti di respirazione che possono migliorare significativamente il movimento nel reparto pantaloni. Una naturale disfunzione erettile soluzioni di trattamento stanno diventando sempre più popolare con gli uomini. Questi rimedi a base di erbe sono preferiti perché non hanno reazioni avverse e sono confermati essere efficiente come il farmaco. La maggior parte degli uomini combattere parlano dei loro problemi, in particolare la disfunzione erettile come c è poca discussione sui problemi di erezione. La verita e che ED ha un impatto su piu di dieci milioni di uomini solo negli Stati Uniti. Non siete soli e l aiuto è disponibile.

Vinay raja, m

VINAY RAJA, M.D.
CURRICULUM VITAE
PROFESSIONAL DESIGNATION

Licensed to Practice Medicine:
Hawaii

Board Certifications:


Additional Credentials:
Home Health Care Examination - Attested by the Institute for EDUCATIONAL BACKGROUND
The University of Texas Medical Branch at Galveston Fellowship in Medical Oncology
John A. Burns School of Medicine, University of Hawaii. (John A. Hartford Foundation Center of Excellence in Geriatrics) Fellowship in Geriatric Medicine July
Mount Sinai School of Medicine/Jersey City Medical Center Chief Medical Resident, Internal Medicine July
Residency in Internal Medicine July
Rotating
Internship
Bachelor of Medicine/Bachelor of Surgery (MBBS) Aug. 1988-Feb. 1993
VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 2
Pre-Medical Education
Physics, Chemistry, Mathematics and Biology PROFESSIONAL EXPERIENCE
PROFESSIONAL APPOINTMENTS
Phelps County Regional Medical Center, Cancer Registry Data Quality Assurance Coordinator
PROFESSIONAL AND BOARD AFFILIATIONS
HOSPITAL AFFILIATIONS
PUBLICATIONS AND ABSTRACTS

Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita S, Clowney B,
Silberstein P. Darbepoetin alfa administered every three weeks is effective for the
treatment of chemotherapy-induced anemia. Oncologist. 2006 Apr;11(4):409-17.
April 2006
Raja V, Balakrishnan R, Bollinger W, Crabtree D, Downey E, Mohindra M:
Double Diagnosis in Cancer Patients and Cutaneous Reaction Related to
Gemcitabine: CASE 2. Mixed Carcinoid-Adenocarcinoma of the Appendix. J
Clinical Oncology. 2005 Oct. 1; 23(28):7223-4. October 2005
VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 3

Raja V, Bryant B, Bessman DJ, Alperin JB: Soft Tissue Sarcomas: CASE 1.
Granulocytic Sarcoma: Presentation With Nodal and Skin Involvement: J Clin
Oncology. 2004 May 15;22(10):2026-7. May 2004
Raja V, Campbell GA: Unusual Cases Involving the CNS and Nasal Sinuses:
CASE 2. SINONASAL UNDIFFERENTIATED CARCINOMA: J Clin
Oncol. 2003 Oct: 3877-3880. October 2003
Raja V, Bessman D: Uncommon Presentations of Malignancies: CASE 4.
TUMOR IMPLANTATION AFTER PNEUMONECTOMY FOR LUNG
CANCER: J Clin Oncol. 2003 Aug 1; 21(15): 2998-9. August 2003
Boroumand N, Raja V, Jones DV, Haque AK:SYT-SSX2 variant of primary
pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a
poor clinical outcome. Arch Pathol Lab Med. 2003 April;127(4):e201-4. April
2003
Raja V, Lin JT, Xiao SY: Unusual Abdominal Tumors: CASE 2. INTRA-
ABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR. J Clin
Oncol. 2003 Mar 1;21(5):951-953. March 2003
Raja V, Montoya M: INTRAMEDULLARY SPINAL CORD METASTASIS
FROM MELANOMA: A CASE REPORT AND REVIEW OF LITERATURE.
Manuscript submitted to Oncology Spectrums for review. January 2003
Coinvestigator- “ A Prospective Open Label Study of Methyphenidate
(Ritalin) for Treatment of Fatigue in Patients with Cancer” - Ongoing Study.
University of Texas Medical Branch at Galveston. September 2002
Raja V, China C, Masaki KH, Nakano G: Unusual presentations of uncommon
tumors: Case 1. Benign metastasizing pleomorphic adenoma. J Clin Oncol 2002
May 1;20(9):2400-2403. May 2002
Presented at the February 9-10, 2001 Hawaii Chapter Annual Scientific Meeting
of the American College of Physicians - American Society of Internal
Medicine, Poster Session, Honolulu, Hawaii.
Subinvestigator: A Multicenter, Randomized, Double-Blind, Placebo
Controlled Study of Three Fixed Doses of Aripiprazole in the Treatment of
Institutionalized Patients with Psychosis Associated with Dementia of the
Alzheimer’s Type. Bristol-Myers. January 2001-June 2001
VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 4

Squibb Research – Univ of Hawaii, Kuakini Medical Center, 347 N. Kuakini St.
HPM-9, Honolulu, HI 96817.
V. Raja, W.F. Wong, K.H. Masaki. Causes of Death in Patients with Dementia.
Abstract published in Journal of the American Geriatrics Society, April
2001;49:S116.

Presented at the May 9, 2001 John A. Hartford Foundation Center and the
American Federation for Aging Research (AFAR) Fellows Poster Session in
Chicago, Illinois.
Presented at the February 9-10, 2001 Hawaii Chapter Annual Scientific Meeting
of the American College of Physicians - American Society of Internal
Medicine, Poster Session, Honolulu, Hawaii.
Sub-investigator in a WHO Project on “Low Osmolarity Oral Rehydration
Solution in Acute Diarrhea in Pediatric Age Group”, at All India Institute of
Medical Sciences, New Delhi, India. April 1995-October 1995.
RESEARCH

Research on the “Causes of Death in Patients with Dementia”. Presented at the
May 9-13, 2001 Annual Scientific Meeting of the American Geriatrics Society,
Poster Session, Chicago, Illinois. July 2000- June 2001
Research on “Life Expectancy in Patients with Dementia”.
Presented at the February 9-10, 2001 Hawaii Chapter Annual Scientific Meeting
of the American College of Physicians - American Society of Internal
Medicine, Poster Session, Honolulu, Hawaii. July 2000- June 2001
Research Project On “Recognition of EKG lead misplacements”. Participated
at the 1999 New Jersey Chapter Annual Scientific Meeting of the American
College of Physicians, Associates Abstract Competition, New Jersey. August
1998- April 1999
RESEARCH PROTOCOLS - BOND CLINIC 2003-2006
VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 5
A Randomized Multicenter Phase II Study of Gemcitabine/Platinum/Cetuximab vs. Gemcitabine/Platinum as First-Line Treatment for Patients with Advanced/Metastatic Non Small Cell Lung cancer (BMS CA225100) Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC A Randomized, Double-Blind, Placebo Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-Metastatic Breast Cancer (AMG162) Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC A Phase III Randomized Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma (CA225014) Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO; Chun Ho So, MD; Sellas Pecos Coble, DO Research Coordinator: Rhonda Drewel, MA, CCRC A Study to Evaluate the Effectiveness of Aranesp at 300mcg Q3W on Clinical Outcomes in Cancer With Anemia Due to Chemotherapy (20030206) Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO; Chun Ho So, MD; Sellas Pecos Coble, DO Research Coordinator: Rhonda Drewel, MA, CCRC Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim As First- or Second-Line Treatment in Subjects with Locally Advanced or Metastatic Colon Cancer (20020715) Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC A Multicenter, Double-Blind, Placebo-Controlled Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 6
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alpha Administered Once Every 4 Weeks in the Treatment of Subjects with Anemia of Cancer Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Study of Oral CCI-779 Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer Principal Investigator: Vinay Raja, MD Sub-Investigator: Joseph Bond, DO Research Coordinator: Rhonda Drewel, MA, CCRC “An Open Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by LEUKINE (Sargramostim), a Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor”. Protocol # 001.0021 Principal Investigator: Joseph C. Bond, DO Sub-investigator: Edward A. Bruns, DO; Cathy E. Bond, DO; Mary K. Bruns, DO; Gregory V. Maynard, DO; Pecos Coble, DO; Vinay Raja, MD Research Administrator: Linda Schumacher, RN BSN, CCRC Research Coordinator: Rhonda Drewel MA, CCRC: Linda Schumacher, RN, BSN, A Phase III Study of Delayed vs. Immediate Second-line Therapy with Docetaxel after Gemcitibine + Carboplatin in Advanced Non-Small Cell Lung Cancer Principal Investigator: Joseph Bond, DO Sub-Investigator: S. Pecos Coble, DO; Mary K. Bruns, DO; Cathy E. Bond, DO; Research Administrator: Linda Schumacher, RN, BSN, CCRC Research Coordinator: Rhonda Drewel, MA, CCRC; Linda Schumacher, RN, BSN, An Open-label. Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and NESP 20000220 Principal Investigator: Joseph Bond, DO Sub-Investigators: Gregory V. Maynard, DO; Edward Bruns, DO; S. Pecos Research Administrator: Linda Schumacher RN, BSN, CCRC VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 7
Research Coordinator: Rhonda Drewel, MA, CCRC; Linda Schumacher, RN, CCRC Cell Therapeutics Protocol PGT302: CT-2103 vs. Docetaxel for the Salvage Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Principal Investigator: Joseph C. Bond, DO Sub-Investigators: Edward A. Bruns, DO; Sellas Pecos Coble, DO; Chun So, Research Coordinator: Rhonda Drewel, MA, CCRC CT-2103/Carboplatin for Patients Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study (PGT201) Principal Investigator: Joseph Bond, DO Sub-Investigators: Sellas Pecos Coble, DO; Edward Bruns, DO; Chun So, MD; Research Coordinator: Rhonda Drewel, MA, CCRC CT-2103 Single Agent or CT-2103 vs Paclitaxel/Carboplatin for the Treatment of PS=2 Patients with Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study (PGT303) Principal Investigator: Joseph Bond, DO Sub-Investigators: Chun Ho So, MD; Sellas Pecos Coble, DO; Edward A. Bruns, Research Coordinator: Rhonda Drewel, MA, CCRC A Phase III, Double-Blind, Multicenter, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of Virulizin plus Gemcitabine versus Placebo plus Gemcitabine; Optional Second-Line Therapy may Include Continuation of Virulizin or Placebo, Alone or in Combination with 5-Fluorouracil Principal Investigator: Joseph Bond, DO Sub-Investigators: Chun Ho So, MD; Sellas Pecos Coble, DO; Edward A. Bruns, Research Coordinator: Rhonda Drewel, MA, CCRC CA225006: A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma Principal Investigator: Joseph Bond, DO Sub-Investigators: Chun Ho So, MD; Sellas Pecos Coble, DO; Edward A. Bruns, VINAY RAJA, M.D.
CURRICULUM VITAE—PAGE 8
Research Coordinator: Rhonda Drewel, MA, CCRC "A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE plus Irinotecan in Patients with Relapsed or Refractory Colorectal Carcinoma" Millennium Protocol No. M34102-049-VELCADEä Principal Investigator: Joseph Bond, DO Sub-Investigators: Chun Ho So, MD; Sellas Pecos Coble, DO; Edward A. Bruns, Research Coordinator: Rhonda Drewel, MA, CCRC A Phase III Trial of Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated with or Resistant to an Anthracycline and Who Are Taxane Resistant (CA163046) Principal Investigator: Joseph Bond, DO Sub-Investigator: Vinay Raja, MD; Chun Ho So, MD; Sellas Pecos Coble, DO Research Coordinator: Rhonda Drewel, MA, CCRC Randomized Trial of Patient-Specific Vaccination with Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) with Local GM-CSF in First Complete Remission Principal Investigator: Joseph Bond, DO Sub-Investigator: Vinay Raja, MD Research Coordinator: Rhonda Drewel, CCRC PROFESSIONAL MEMBERSHIPS
HONORS AND AWARDS
Distinction Awards - Anatomy, Physiology, Biochemistry, Microbiology

Source: http://kccc.cancercenter.cc/files/2010/01/cv_raja.pdf